MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

21 Dec 2022 16:15:14 By Nasdaq GlobeNewswire

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

18 Dec 2022 16:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results

03 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 08:00:04 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

31 Aug 2022 08:00:02 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

04 Aug 2022 08:00:08 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

25 Jun 2022 09:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Supports International NASH Day on June 9

06 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 Jun 2022 08:00:03 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

17 May 2022 08:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

09 May 2022 06:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

28 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

09 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

24 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

31 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

30 Jan 2022 16:00:00 By Nasdaq GlobeNewswire

Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

10 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

30 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

23 Nov 2021 07:00:00 By Nasdaq GlobeNewswire